Viking Therapeutics Inc. Common Stock (VKTX)

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

65

Website

vikingtherapeutics.com/

Fundamentals

1-day range

$32$33.86

Market cap

$3.80B

P/E (trailing)

—

P/E (forward)

-7.45

EPS (trailing)

$-4.66

Dividend yield

—

Beta

0.61

Avg. volume

2.27M

Forecasts

19 analyst ratings

Viking Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• VKTX

  Viking Therapeutics Inc. Common Stock

  $32.15

  ▼ 5.05%
  Market cap $3.80BP/E —
  $22.96$43.15
• ELVN

  Enliven Therapeutics Inc. Common Stock

  $57.82

  ▼ 4.43%
  Market cap $3.53BP/E —
  $14.79$62.32
• GPCR

  Structure Therapeutics Inc. American Depositary Shares

  $47.38

  ▼ 3.74%
  Market cap $3.44BP/E —
  $18.26$94.9
• TLX

  Telix Pharmaceuticals Limited American Depositary Shares

  $11.28

  ▼ 0.84%
  Market cap $3.39BP/E —
  $6.28$12.5
• MANE

  Veradermics Incorporated Common Stock

  $97.53

  ▼ 4.20%
  Market cap $4.26BP/E —
  $32$131.24
• ALMS

  Alumis Inc. Common Stock

  $22.38

  ▼ 3.58%
  Market cap $3.33BP/E —
  $3.76$31.35
• ARQT

  Arcutis Biotherapeutics Inc. Common Stock

  $23.78

  ▼ 4.38%
  Market cap $3.24BP/E 113.86
  $15.1$31.77

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65
  benzinga · 8/11/2026
• JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65
  Benzinga · 8/11/2026
• Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)
  SeekingAlpha · 8/7/2026
• Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished
  Yahoo · 8/6/2026
• Viking Therapeutics (VKTX) Draws Fresh VK2735 Attention, Is It Still Below Fair Value?
  Yahoo · 8/4/2026
• The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Obesity Dosing Ambitions And Fresh Financing – Learn Why
  Yahoo · 8/4/2026
• Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says
  Yahoo · 8/3/2026

• Dorothy Elizabeth Kelly-Gemmell · August 1, 2026 · Grant

  40.8K
• Dorothy Elizabeth Kelly-Gemmell · August 1, 2026 · Grant

  6.3K
• Brian Lian · July 29, 2026 · Sale

  148.5K @ $33.32
• Marianna Mancini · July 29, 2026 · Sale

  18.2K @ $33.47
• Greg Zante · July 29, 2026 · Sale

  21.2K @ $33.47
• Brian Lian · July 28, 2026 · Grant

  221.7K
• Marianna Mancini · July 28, 2026 · Grant

  31.7K
• Greg Zante · July 28, 2026 · Grant

  31.7K
• Chen Hubert C · June 1, 2026 · Grant

  190.0K
• Neil William Aubuchon · March 10, 2026 · Buy

  4.5K @ $33.5

Institutional Ownership

March 31, 2026

Total shares held

75.29M

Total value held

$2.48B

Institutional holders

403